Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus gel for facial angiofibroma associated with tuberous sclerosis complex
CTR20253386Phase 4Active
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sirolimus in tuberous sclerosis complex (TSC) and facial angiofibroma, sponsored by Nobelpharma Co., Ltd. Primary endpoint: Improvement rate of angiofibroma as assessed by the independent review committee. Started Sep 2025; status: active.
02
Drugs
sirolimus
03
Conditions
tuberous sclerosis complex (TSC)facial angiofibroma
Beyond the preview
Go deeper on CTR20253386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253386.